Editorial
A New Era in the Treatment of Scleroderma-associated Interstitial Lung Disease?
D. Launay ....................................................... 1619

Articles
Predictive Value of Arterial Stiffness and Subclinical Carotid Atherosclerosis for Cardiovascular Disease in Patients with RA
ACR/EULAR Definitions of Remission Are Associated with Lower Residual Inflammatory Activity Compared with DAS28 Remission on Hand MRI in RA
M.P. Lisbona, A. Solano, J. Ares, M. Almirall, T.C. Salman-Monte, J. Maymó ........................................... 1631
Toreforant, A Histamine H4 Receptor Antagonist, in Patients with Active RA Despite MTX Therapy: Results of 2 Phase II Studies
Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in RA: Results from an Australian Early Arthritis Cohort
N.T. Wabe, M.J. Sorich, M.D. Wechalekar, et al ........................................ 1643
Infection in Southern Chinese Patients with SLE: Spectrum, Drug Resistance, Outcomes, and Risk Factors
D. Chen, J. Xie, H. Chen, et al ........................................ 1650
Associations of the Levels of C4d-bearing Reticulocytes and High-avidity Anti-dsDNA Antibodies with Disease Activity in SLE
C. Mora, J. Medina-Rosas, A.M. Santos, et al ........................................ 1657
The Recurrence of Digital Ulcers in Patients with SSc after Discontinuation of Oral Treprostinil
A.A. Shah, E. Schiopu, S. Chatterjee, et al ........................................ 1665
An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial
D. Khanna, C. Albera, A. Fischer, et al ........................................ 1672

The Minimum Clinically Important Improvement and Patient-acceptable Symptom State in the BASDAI and BASFI for Patients with Ankylosing Spondylitis
M.J. Kviatkovsky, S. Ramiro, R. Landewé, et al ........................................ 1680
Development of a Screening Tool for the Identification of Sacroiliitis in CT Scans of the Abdomen
J. Chan, I. Sarl, D. Salonen, R.D. Inman, N. Haroon ........................................ 1687
Involvement of Mucosal-associated Invariant T cells in Ankylosing Spondylitis
E. Hayashi, A. Chiba, K. Tada, et al ........................................ 1695
Serum CRP Levels Demonstrate Predictive Value for Radiographic and MRI Outcomes in Patients with Active Ankylosing Spondylitis Treated with Golimumab
J. Braun, X. Baraliakos, K.G. Hermann, S. Xu, B. Hsu ........................................ 1704
Efficacy of Subcutaneous Secukinumab in Patients with Active PsA Stratified by Prior TNF Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study
A. Kavanaugh, I.B. McInnes, P.J. Mease, et al ........................................ 1713
Attainment of Minimal Disease Activity Using MTX in PsA
B.J. Sheane, A. Thavaneswaran, D.D. Gladman, V. Chandran ........................................ 1718
A Phase III, Randomized, Controlled Trial of Apremilast in Patients with PsA: Results of the PALACE 2 Trial
Gottron Papules and Gottron Sign with Ulceration: A Distinctive Cutaneous Feature in a Subset of Patients with Classic Dermatomyositis and Clinically Amyopathic Dermatomyositis
H. Cao, Q. Xia, M. Pan, et al ........................................ 1735
Widespread Pain and Low Widespread Pain Index Scores among FM-positive Cases Assessed with the 2010/2011 FM Criteria
F. Wolfe, N. Eglolf, W. Häuser ........................................ 1743
The Effect of the Presence of FM on Common Clinical Disease Activity Indices in Patients with PsA: A Cross-sectional Study
S. Brikman, V. Furer, J. Wollman, et al ........................................ 1749